imagine that you have a store where you sell candies. In the past few months, many people have been buying your candies, and they are happy with them. You also have new kinds of candies that other candy stores don't have, and that makes your store special. But, there are also other candy stores and sometimes, people don't want to buy your candies because they can buy the same candies for less money from other stores. Also, some of the candies you sell are made in other countries, and the price of those candies can change because of something called "exchange rate." So, you have to keep an eye on that to make sure you can sell your candies at a good price. Read from source...

This, as Benzinga's article on Inogen highlights the company's strong Q2 results, a robust year-over-year uptick in domestic and international business-to- business sales, a solid year-over-year top and bottom-line performance and expansion of the adjusted gross margin. The article, however, notes stiff competition and forex volatility as major downsides.

Add Inogen stock to your portfolio now, as it is well-positioned for growth, thanks to its solid first-quarter 2024 performance and strong product portfolio. Inogen's market capitalization is at $268.7 million, with projected 56.6% growth for 2024, making its valuation attractive compared to the industry's 3.1X. The company's proprietary Inogen One and Inogen Rove systems offer supplemental long-term oxygen therapy anytime, anywhere, with a battery that can be plugged into an outlet. However, stiff competition and forex volatility remain major downsides. Inogen is witnessing an improving estimate revision trend for 2024, with a Zacks Consensus Estimate for 2024 revenues of $327 million.